Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
LUCD
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-0.23
vs -0.28
Q3.23
N/A
-0.24
vs -0.28
Q4.23
N/A
-0.23
vs -0.29
Q1.24
N/A
-0.21
vs -0.24
Q2.24
N/A
-0.20
vs -0.23
Q3.24
N/A
-0.20
vs -0.24
Q4.24
N/A
-0.19
vs -0.23
Q1.25
N/A
-0.16
vs -0.21
Q2.25
N/A
-0.11
vs -0.20
Q3.25
N/A
-0.11
vs -0.20
Sales Growth
YoY
Current
Estimates
Q2.23
NA
159K vs NA
Q3.23
+930%
783K vs 76K
Q4.23
+829%
1M vs 112K
Q1.24
+124%
1M vs 446K
Q2.24
+514%
976K vs 159K
Q3.24
+50%
1.2M vs 783K
Q4.24
+15%
1.2M vs 1M
Q1.25
-17%
828K vs 1M
Q2.25
+18%
1.2M vs 976K
Q3.25
+52%
1.8M vs 1.2M
Return on Equity
QoQ
Q2.23
-76%
-0.76
vs -79.47
Q3.23
-556%
-5.56
vs -0.76
Q4.23
+469%
4.69
vs -5.56
Q1.24
-89%
-0.89
vs 4.69
Q2.24
-69%
-0.69
vs -0.89
Q3.24
-195%
-1.95
vs -0.69
Q4.24
-214%
-2.14
vs -1.95
Q1.25
+670%
6.7
vs -2.14
Institutionnal Ownership
QoQ
Q2.23
16
16
vs 18
-11%
Q3.23
23
23
vs 16
44%
Q4.23
24
24
vs 23
4%
Q1.24
28
28
vs 24
17%
Q2.24
32
32
vs 28
14%
Q3.24
27
27
vs 32
-16%
Q4.24
32
32
vs 27
19%
Q1.25
46
46
vs 32
44%
prnewswire.com
7 hours ago
prnewswire.com
8 hours ago
prnewswire.com
8 hours ago
zacks.com
10 hours ago
seekingalpha.com
13 hours ago
Quote Panel
Key Metrics
Forecast
2198%2026-Revenue
37%2026-EPS
57%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
Zacks Investment Research
downgradePrevious: Not converted
2022-04-26
Now: Sell
Relative Strength
LUCD
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
-0.02Â ( -1.90%)
Relative Strenght
37
Volume Buzz
-17%
Earning Acce
Yes
Dist 52w H.
43%